UK Community Advisory Board (UK-CAB)

UK-CAB40: Gender and HIV Research


09:30 – 09:45 Registration, refreshments and expenses
09:45 – 10:00 Welcome, introductions, UKCAB updates, Company pre-meeting
10:00 – 10:30 Gender and HIV research: history and overview – Polly Clayden, HIV i-Base
10:30 – 11.30 Outcomes in HIV positive women – Lucy Campbell, Kings College Hospital
11:30 – 11:40 Break
11:40 – 12:40 HIV and women’s issues – Prof. Jane Anderson
12:40 – 14:00 Lunch
14:00 – 15:30 Company meeting: BMS
15.30 – 15.35 Break
15:35 – 16:00 London HIV drug prescribing update and survey Mark Platt
16.00 Close

Background reading:
1st International Workshop on Women From Adolescence through menopause

The full report from this meeting can be viewed online here:
Lopinavir/ritonavir LPV/r: women versus men
An analysis of on efficacy, safety and tolerability of LPV/r in women compared to men

Lessons from GRACE: A US Study Focused on Women Living with HIV
GRACE is the largest HIV/AIDS study to date in North America of HIV treatment experienced women. The study looked at whether darunavir/ritonavir (DRV/r) in combination with other ARVs would have a different effect in women compared to men. Black women were the focus of the GRACE Study because of the disproportionate effect that HIV/AIDS has in this population throughout the US.
It also is reportedly the longest ongoing disease progression study of HIV infection in women.

Quality of life in the GRACE study
The report looks at the quality of life in the study participants and how it impacted on discontinuing the study and virological response.

Antiretroviral pharmacokinetics in women with undetectable viral load
Considerations Regarding Antiretroviral Therapy in HIV-positive Women: Pharmacokinetics

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.